Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction

The objective of this clinical trial was to assess the safety and efficacy of carotid BAT in advanced HF. Published in the JACC: Heart Failure, it concluded, “BAT is safe and improves functional status, quality of life, exercise capacity, N-terminal pro-brain natriuretic peptide, and possibly the burden of heart failure hospitalizations in patients with GDMT-treated NYHA class III HF.”

Read the Full Article

A presentation is also available to accompany this article.